Sleep-related experimental peptide · Fact sheet

DSIP

Also known as Delta sleep-inducing peptide · Emideltide

DSIP is an experimental peptide named for early sleep research. Small human studies do not establish it as an effective insomnia treatment; one controlled study found weak objective effects and no subjective sleep improvement.

Not FDA approvedLimited or unclear evidence

What is DSIP?

Delta sleep-inducing peptide is also called emideltide. Its name describes a research history, not a proven clinical result.

Benefits & claims

Deeper sleep, fewer awakenings, and improved next-day recovery are common expectations. The distinction between a subjective experience and measured sleep improvement matters here.

What the evidence supports

  • Some early reports suggested sleep effects, but later controlled findings were weak and inconsistent.
  • The 16-person study did not show improved subjective sleep quality.
Research areas
  • Insomnia
  • Sleep efficiency
  • Sleep physiology

Dosage & frequency

No established human regimen

Small, older human sleep experiments do not establish a reproducible DSIP treatment regimen. There is no FDA-approved DSIP sleep medicine.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Sleep-related study findings do not establish equivalence among injected or intranasal preparations.

Interactions & precautions

  • Small sleep experiments do not establish compatibility with sedatives, sleep medicines, or other CNS-active treatments.

What is still unresolved

  • Consistent efficacy, formulation, timing, and long-term safety remain unresolved.

Side effects & risks

  • FDA describes peptide-quality concerns and inadequate safety information for proposed routes.
  • Small historical studies cannot establish the likelihood of uncommon harms or effects of prolonged exposure.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

The historical human literature is small. A double-blind study of 16 people with chronic insomnia did not find a major therapeutic benefit; some apparent changes could reflect differences in the placebo group.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Deeper-feeling sleep, with inconsistent or fading effects

Comments in one discussion include descriptions of deeper sleep, feeling more rested without longer sleep, and a follow-up saying the initial benefit had faded.

Amount, frequency, route and duration could not be confirmed for this account.

These are different people with uncontrolled sleep problems and other exposures. No sleep-laboratory measurements verify deeper sleep, and the thread cannot establish tolerance or durability.

Read the DSIP discussion

Approval status

DSIP is not an FDA-approved insomnia medicine. The cited older studies should not be presented as an active late-stage development program.

Historical studies; no FDA-approved sleep use

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Reproducible benefit for chronic insomnia
  • Effects on next-day function
  • Long-term safety and medication interactions

Summary

Small, inconsistent studies have not established a dependable sleep benefit.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety concerns for selected bulk substances

    Ingredient-specific safety findings; compounding review is not drug approval.

  2. pubmedDSIP in chronic insomnia: a controlled study

    Small matched-pairs double-blind study; weak objective effects and no subjective improvement.

  3. pubmedEarly DSIP insomnia report

    Historical report with limited detail in the indexed record.

How we assess sources · Suggest a correction